Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Titel:
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Auteur:
Ahn, Myung J. Kim, Hye R. Yang, James C.H. Han, Ji-Yu Li, Jacky Yu-Chung. Hochmair, Maximilian J. Chang, Gee-Chen Delmonte, Angelo Lee, Ki H. Campelo, Rosario G. Gridelli, Cesare Spira, Alexander I. Califano, Raffaele Griesinger, Frank Ghosh, Sharmistha Felip, Enriqueta Kim, Dong-Wan Liu, Yuyin Zhang, Pingkuan Popat, Sanjay Camidge, D. Ross